CDH3 and central nervous system cancer: Focusing on each WHO malignancy grade, independently of IDH mutation and 1p/19q codeletion status, the frequency of CDH3 overexpression increased with higher tumor grades (8.5% in grade II, 15.0% in grade III, and 21.3% in grade IV gliomas).